Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224668) LONG NON-CODING RNA IN CANCER
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A polynucleotide that is able to bind to and inhibit a long non-coding RNA transcript that comprises or consists of the sequence SEQ ID NO 1 or SEQ ID NO 2.

2. The polynucleotide according to claim 1 where the long non-coding RNA comprises or consist of the sequence of SEQ ID NO 1.

3. The polynucleotide according to claim 1 where the long non-coding RNA comprises or consist of the sequence of SEQ ID NO 2.

4. The polynucleotide according to any one of claim 1 to 3 where the polynucleotide binds to a part of SEQ ID NO 3.

5. The polynucleotide of any one of claims 1 to 4 where the polynucleotide binds to a sequence selected from SEQ ID NO 14 to SEQ ID NO 20.

6. The polynucleotide according to any one of claims 1 to 5 where the polynucleotide is a DNA antisense polynucleotide selected from SEQ ID NO 4 and SEQ ID NO 5, a shRNA polynucleotide selected from SEQ ID NO 6 and SEQ ID NO 7, or a siRNA polynucleotide which is a duplex of SEQ ID NO 8 and SEQ ID NO 9, a duplex of SEQ ID NO 10 and SEQ ID NO 11 or a duplex of SEQ ID NO 12 and SEQ ID NO 13.

7. A polynucleotide according to any claim 1 or 6 for use in the treatment of a disease.

8. The polynucleotide for use according to claim 7 where the disease is cancer.

9. The polynucleotide for use according to claim 8 where the cancer is lung cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, prostate cancer or endometrial cancer.

10. The polynucleotide for use according to any one of claims 8 or 9 where the cancer is resistant against chemotherapy.

11. The polynucleotide for use according to claim 10 where the cancer is resistant against a platinum-based chemotherapeutic agent.

12. A pharmaceutical composition comprising a polynucleotide according to any one of claims 1 to 6.

13. A method for treatment comprising administering to a patient a polynucleotide according to any one of claims 1 to 6.

14. A polynucleotide that detects the long non-coding RNA of SEQ ID NO 1 or SEQ ID NO 2 for use in diagnosis.

15. A polynucleotide for use according to claim 14 where the diagnosis is diagnosis of cancer.

16. A polynucleotide for use according to claim 15 where the cancer is selected from the group consisting of kidney cancer or liver cancer.

17. A method for diagnosis comprising detecting an RNA transcript comprising SEQ ID NO 3, SEQ ID NO 1 or SEQ ID NO 2 in a sample of a patient.

18. The method of claim 17 where the diagnosis is diagnosis of cancer.

19. A polynucleotide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO 4 toSEQ ID NO 13.